Evidence map›Paper›PMID 42569042›Full record

ArticleACS omega2026

Structure-Activity Relationship Study of Antimalarial Asparagine-Derived Proteasome Inhibitors.

Hao Zhang, Daqiang Li, Hao-Chi Hsu, Akshay Vishwanatha, Wenhu Zhan, Takafumi Yukawa, Joseph Visone, Toshihiro Imaeda, Rei Okamoto, Pavla Fajtova and 18 more

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Hao ZhangDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States.ORCID https://orcid.org/0000-0002-1187-5844
Daqiang LiDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States.
Hao-Chi HsuDepartment of Structural Biology, Van Andel Institute, Grand Rapids, Michigan 49503, United States.
Akshay VishwanathaDepartment of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States.
Wenhu ZhanDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States.
Takafumi YukawaSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.
Joseph VisoneDepartment of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States.
Toshihiro ImaedaSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.
Rei OkamotoSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.
Pavla FajtovaCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Ryoma HaraSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.
Masanori KawasakiSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.
Kenjiro SatoSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.ORCID https://orcid.org/0009-0006-0674-0239
Mayako MichinoSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.ORCID https://orcid.org/0000-0002-5469-025X
Shreeya GargDepartment of Medicine, University of California, San Francisco, California 94143, United States.
Oriana KreutzfeldDepartment of Medicine, University of California, San Francisco, California 94143, United States.
Patrick K TumwebazeInfectious Diseases Research Collaboration, Kampala, Uganda.
Stephen OrenaInfectious Diseases Research Collaboration, Kampala, Uganda.
Martin OkitwiInfectious Diseases Research Collaboration, Kampala, Uganda.
Kazuyoshi AsoSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.
Roland A CooperDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California 94901, United States.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, California 94143, United States.
Peter T MeinkeSanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.ORCID https://orcid.org/0000-0002-7548-6215
Michael FoleySanders Tri-Institutional Therapeutics Discovery Institute, 1230 York Ave., New York, New York 10065, United States.
Anthony J O'DonoghueCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Huilin LiDepartment of Structural Biology, Van Andel Institute, Grand Rapids, Michigan 49503, United States.ORCID https://orcid.org/0000-0001-8085-8928
Laura A KirkmanDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States.
Gang LinDepartment of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave, New York, New York 10065, United States.ORCID https://orcid.org/0000-0003-4797-7073

Funding

Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipelineR01AI139179 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Philip Jon Rosenthal · 2018 to 2026
$6.3M
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarialsR01AI143714 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Gang Lin · 2019 to 2026
$6.1M
Proteasome inhibitors against mucosal protozoan pathogensR01AI158612 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, O'DONOGHUE, ANTHONY JOHN · 2021 to 2025
$3.2M
Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistanceR01AI177635 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Gang Lin · 2023 to 2026
$3.1M
Novel Inhibitors of Malaria ProteasomeR21AI123794 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI KIRKMAN, LAURA, LIN, GANG · 2017 to 2018
$466k
New tools to facilitate drug discovery for pathogen proteasomesR21AI188258 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAFFREY, CONOR, O'DONOGHUE, ANTHONY JOHN · 2025 to 2025
$439k
NIAID NIH HHS R01 AI139179NIAID NIH HHS R01 AI143714NIAID NIH HHS R01 AI158612NIAID NIH HHS R01 AI177635NIAID NIH HHS R21 AI123794NIAID NIH HHS R21 AI188258
6 · The paper itself

Abstract

Malaria remains a significant global health threat, affecting millions of lives each year. The causative agents,

Identifiers

PMID42569042
PMCPMC13448977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.